Table 3.
Univariate analysis of OS according to tumor subtype and as a function of best cutoff value.
| OS | ||||||
|---|---|---|---|---|---|---|
| Number of patients | Number of events | Median OS (months) (95% CI) |
p | HR (95% CI) |
p | |
| Triple-negative | ||||||
| Overall | 124 | 61 | 15.9 (12.2–20.6) | – | – | – |
| CTC <5 | 82 | 37 | 17.8 (15.6–36.3) | 1.00 | ||
| ⩾5 | 42 | 24 | 11.1 (9.1–12.2) | 0.011 | 1.96 (1.16–3.33) | 0.012 |
| NLR <3 | 62 | 32 | 15.9 (13.2–27.4) | 1.00 | ||
| ⩾3 | 62 | 29 | 15.8 (10.4–24.4) | 0.442 | 1.22 (0.73–2.03) | 0.443 |
| PLR <210 | 57 | 26 | 18.2 (14.0–40.1) | 1.00 | ||
| ⩾210 | 67 | 35 | 14.5 (10.6–16.7) | 0.129 | 1.49 (0.89–2.50) | 0.132 |
| SII <836 | 65 | 33 | 15.9 (13.2–27.4) | 1.00 | ||
| ⩾836 | 59 | 28 | 15.8 (10.6–24.4) | 0.521 | 1.18 (0.71–1.97) | 0.522 |
| MLR <0.34 | 50 | 21 | 20.6 (15.6–40.1) | 1.00 | ||
| ⩾0.34 | 74 | 40 | 11.9 (9.0–15.9) | 0.011 | 1.99 (1.16–3.41) | 0.013 |
| HER2+ | ||||||
| Overall | 100 | 36 | 34.5 (21.2–nr) | – | – | – |
| CTC <5 | 65 | 20 | 34.5 (21.2–nr) | 1.00 | ||
| ⩾5 | 35 | 16 | 23.0 (10.5–nr) | 0.170 | 1.58 (0.82–3.05) | 0.174 |
| NLR <3 | 63 | 18 | 34.5 (23.0–nr) | 1.00 | ||
| ⩾3 | 37 | 18 | 21.2 (10.3–nr) | 0.094 | 1.74 (0.90–3.34) | 0.098 |
| PLR <210 | 60 | 14 | 34.5 (30.4–nr) | 1.00 | ||
| ⩾210 | 40 | 22 | 17.3 (13.3–nr) | 0.010 | 2.36 (1.21–4.62) | 0.012 |
| SII <836 | 63 | 20 | 34.5 (18.8–nr) | 1.00 | ||
| ⩾836 | 37 | 16 | 27.2 (16.2–nr) | 0.517 | 1.24 (0.64–2.40) | 0.517 |
| MLR <0.34 | 50 | 12 | 34.5 (27.2–nr) | 1.00 | ||
| ⩾0.34 | 50 | 24 | 21.2 (14.4–nr) | 0.026 | 2.16 (1.08–4.33) | 0.029 |
| HER2– ER+ | ||||||
| Overall | 280 | 83 | 27.7 (22.2–40.6) | – | – | – |
| CTC <5 | 156 | 31 | nr | 1.00 | ||
| ⩾5 | 124 | 52 | 20.5 (17.3–26.6) | <0.0001 | 2.44 (1.56–3.81) | <0.0001 |
| NLR <3 | 156 | 40 | 27.7 (23.9–nr) | 1.00 | ||
| ⩾3 | 124 | 43 | 21.6 (17.8–nr) | 0.069 | 1.49 (0.97–2.29) | 0.071 |
| PLR <210 | 170 | 47 | 26.6 (22.1–nr) | 1.00 | ||
| ⩾210 | 110 | 36 | 29.0 (20.1–nr) | 0.533 | 1.15 (0.74–1.77) | 0.534 |
| SII <836 | 164 | 39 | 29.0 (24.1–nr) | 1.00 | ||
| ⩾836 | 116 | 44 | 21.6 (19.1–nr) | 0.055 | 1.52 (0.99–2.34) | 0.057 |
| MLR <0.34 | 150 | 39 | 29.0 (23.5–nr) | 1.00 | ||
| ⩾0.34 | 130 | 44 | 23.9 (19.3–nr) | 0.091 | 1.45 (0.94–2.23) | 0.093 |
CTC, circulating tumor cell; ER, estrogen receptor; MLR, monocyte–lymphocyte ratio; nr, nor reached; NLR, neutrophil–lymphocyte ratio; OS, overall survival; PFS, progression-free survival; PLR, platelet–lymphocyte ratio; SII, systemic immune-inflammation index.